# Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

> **NCT01229644** · PHASE2 · TERMINATED · sponsor: **Arog Pharmaceuticals, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Crenolanib (CP-868,596)

## Key facts

- **NCT ID:** NCT01229644
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-04
- **Primary completion:** 2012-06
- **Final completion:** 2012-12
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229644, "Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01229644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*